Validation and comparison of Breast Graded Prognostic Assessment scores in patients with breast cancer and brain metastases

[1] Zimm S(1981)Intracerebral metastases in solid-tumor patients: natural history and results of treatment Cancer 48 384-394

[2] Wampler GL(2000)Radiation therapy in the management of brain metastases from breast cancer Breast Cancer Res Treat 62 211-216

[3] Stablein D(2018)External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: a multicentric European experience Breast 37 36-41

[4] Fokstuen T(2012)Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases J Clin Oncol 30 419-425

[5] Wilking N(2015)Validation and development of a modified breast graded prognostic assessment as a tool for survival in patients with breast cancer and brain metastases J Clin Oncol 33 2239-2245

[6] Rutqvist LE(2017)Brain metastases in newly diagnosed breast cancer: a population-based study JAMA Oncol 3 1069-1077

[7] Griguolo G(2008)Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases Cancer 113 2638-2645

[8] Jacot W(2005)Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659-1672

[9] Kantelhardt E(2013)CNS metastases in breast cancer: old challenge, new frontiers Clin Cancer Res 19 6404-6418

[10] Sperduto PW(2014)Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2—positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831 J Clin Oncol 32 3744-3752

[1] Zimm S(1981)Intracerebral metastases in solid-tumor patients: natural history and results of treatment Cancer 48 384-394

[2] Wampler GL(2000)Radiation therapy in the management of brain metastases from breast cancer Breast Cancer Res Treat 62 211-216

[3] Stablein D(2018)External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: a multicentric European experience Breast 37 36-41

[4] Fokstuen T(2012)Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases J Clin Oncol 30 419-425

[5] Wilking N(2015)Validation and development of a modified breast graded prognostic assessment as a tool for survival in patients with breast cancer and brain metastases J Clin Oncol 33 2239-2245

[6] Rutqvist LE(2017)Brain metastases in newly diagnosed breast cancer: a population-based study JAMA Oncol 3 1069-1077

[7] Griguolo G(2008)Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases Cancer 113 2638-2645

[8] Jacot W(2005)Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659-1672

[9] Kantelhardt E(2013)CNS metastases in breast cancer: old challenge, new frontiers Clin Cancer Res 19 6404-6418

[10] Sperduto PW(2014)Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2—positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831 J Clin Oncol 32 3744-3752